These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 32402949)
1. Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses. Kwiatkowski K; Ciapała K; Rojewska E; Makuch W; Mika J Int Immunopharmacol; 2020 Jul; 84():106540. PubMed ID: 32402949 [TBL] [Abstract][Full Text] [Related]
2. Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy. Kwiatkowski K; Pawlik K; Ciapała K; Piotrowska A; Makuch W; Mika J Front Immunol; 2020; 11():615327. PubMed ID: 33408720 [TBL] [Abstract][Full Text] [Related]
3. Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats. Kwiatkowski K; Piotrowska A; Rojewska E; Makuch W; Jurga A; Slusarczyk J; Trojan E; Basta-Kaim A; Mika J Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():68-78. PubMed ID: 26190414 [TBL] [Abstract][Full Text] [Related]
4. The RS504393 Influences the Level of Nociceptive Factors and Enhances Opioid Analgesic Potency in Neuropathic Rats. Kwiatkowski K; Piotrowska A; Rojewska E; Makuch W; Mika J J Neuroimmune Pharmacol; 2017 Sep; 12(3):402-419. PubMed ID: 28337574 [TBL] [Abstract][Full Text] [Related]
5. A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model. Bober A; Piotrowska A; Pawlik K; Ciapała K; Maciuszek M; Makuch W; Mika J Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000516 [TBL] [Abstract][Full Text] [Related]
6. Chemokines CCL2 and CCL7, but not CCL12, play a significant role in the development of pain-related behavior and opioid-induced analgesia. Kwiatkowski K; Popiolek-Barczyk K; Piotrowska A; Rojewska E; Ciapała K; Makuch W; Mika J Cytokine; 2019 Jul; 119():202-213. PubMed ID: 31003094 [TBL] [Abstract][Full Text] [Related]
7. CC Chemokine Family Members' Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury-A Review of Clinical and Experimental Findings. Ciechanowska A; Mika J Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612597 [TBL] [Abstract][Full Text] [Related]
8. Contribution of chemokine CCL2/CCR2 signaling in the dorsal root ganglion and spinal cord to the maintenance of neuropathic pain in a rat model of lumbar disc herniation. Zhu X; Cao S; Zhu MD; Liu JQ; Chen JJ; Gao YJ J Pain; 2014 May; 15(5):516-26. PubMed ID: 24462503 [TBL] [Abstract][Full Text] [Related]
9. Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain. Pawlik K; Mika J Molecules; 2023 Jul; 28(15):. PubMed ID: 37570736 [TBL] [Abstract][Full Text] [Related]
10. Metamizole relieves pain by influencing cytokine levels in dorsal root ganglia in a rat model of neuropathic pain. Zajaczkowska R; Kwiatkowski K; Pawlik K; Piotrowska A; Rojewska E; Makuch W; Wordliczek J; Mika J Pharmacol Rep; 2020 Oct; 72(5):1310-1322. PubMed ID: 32691345 [TBL] [Abstract][Full Text] [Related]
11. The blockade of CC chemokine receptor type 1 influences the level of nociceptive factors and enhances opioid analgesic potency in a rat model of neuropathic pain. Pawlik K; Piotrowska A; Kwiatkowski K; Ciapała K; Popiolek-Barczyk K; Makuch W; Mika J Immunology; 2020 Apr; 159(4):413-428. PubMed ID: 31919846 [TBL] [Abstract][Full Text] [Related]
12. Direct and indirect pharmacological modulation of CCL2/CCR2 pathway results in attenuation of neuropathic pain - In vivo and in vitro evidence. Piotrowska A; Kwiatkowski K; Rojewska E; Slusarczyk J; Makuch W; Basta-Kaim A; Przewlocka B; Mika J J Neuroimmunol; 2016 Aug; 297():9-19. PubMed ID: 27397071 [TBL] [Abstract][Full Text] [Related]
13. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. Visseaux B; Charpentier C; Collin G; Bertine M; Peytavin G; Damond F; Matheron S; Lefebvre E; Brun-Vézinet F; Descamps D; PLoS One; 2015; 10(8):e0134904. PubMed ID: 26247470 [TBL] [Abstract][Full Text] [Related]
14. Maraviroc reduces neuropathic pain through polarization of microglia and astroglia - Evidence from in vivo and in vitro studies. Piotrowska A; Kwiatkowski K; Rojewska E; Makuch W; Mika J Neuropharmacology; 2016 Sep; 108():207-19. PubMed ID: 27117708 [TBL] [Abstract][Full Text] [Related]
15. CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. Kim MB; Giesler KE; Tahirovic YA; Truax VM; Liotta DC; Wilson LJ Expert Opin Investig Drugs; 2016 Dec; 25(12):1377-1392. PubMed ID: 27791451 [TBL] [Abstract][Full Text] [Related]
16. New insights into the analgesic properties of the XCL1/XCR1 and XCL1/ITGA9 axes modulation under neuropathic pain conditions - evidence from animal studies. Ciechanowska A; Rojewska E; Piotrowska A; Barut J; Pawlik K; Ciapała K; Kreiner G; Mika J Front Immunol; 2022; 13():1058204. PubMed ID: 36618360 [TBL] [Abstract][Full Text] [Related]
18. CCR4 Antagonist (C021) Administration Diminishes Hypersensitivity and Enhances the Analgesic Potency of Morphine and Buprenorphine in a Mouse Model of Neuropathic Pain. Bogacka J; Ciapała K; Pawlik K; Kwiatkowski K; Dobrogowski J; Przeklasa-Muszynska A; Mika J Front Immunol; 2020; 11():1241. PubMed ID: 32760393 [TBL] [Abstract][Full Text] [Related]
19. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680 [TBL] [Abstract][Full Text] [Related]
20. CCR4 antagonist (C021) influences the level of nociceptive factors and enhances the analgesic potency of morphine in a rat model of neuropathic pain. Bogacka J; Popiolek-Barczyk K; Pawlik K; Ciechanowska A; Makuch W; Rojewska E; Dobrogowski J; Przeklasa-Muszynska A; Mika J Eur J Pharmacol; 2020 Aug; 880():173166. PubMed ID: 32407723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]